GlassScriptPhysician profile
Jignesh Desai
NPI 1265857114
$924.28
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.27 · 2021: $120 · 2022: $27.53 · 2023: $319 · 2024: $268 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $256.95 | 2023-2025 | Fetroja |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.43 | 2023-2025 | Xifaxan |
| Pfizer INC. | $106.92 | 2023-2024 | |
| Silk Road Medical, INC. | $104.63 | 2021 | |
| Merck Sharp & Dohme LLC | $75.59 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Hologic Sales and Service, LLC | $57.46 | 2021-2023 | Affirm Prone Biopsy System |
| Abbvie INC. | $35.90 | 2023-2025 | Teflaro |
| Novo Nordisk INC | $30.31 | 2020-2023 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $27.94 | 2023 | Seglentis |
| Allergan, INC. | $21.78 | 2020 | |
| Boston Scientific Corporation | $21.39 | 2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $17.37 | 2024 | Camzyos |
| Lilly USA, LLC | $15.59 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.02 | 2023 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jignesh Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.